NASDAQ:TLSA - Tiziana Life Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.50
  • Forecasted Upside: 239.29 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.80
▼ -0.24 (-7.89%)
1 month | 3 months | 12 months
Get New Tiziana Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TLSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TLSA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.50
▲ +239.29% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Tiziana Life Sciences in the last 3 months. The average price target is $9.50, with a high forecast of $11.00 and a low forecast of $8.00. The average price target represents a 239.29% upside from the last price of $2.80.
Buy
The current consensus among 2 contributing investment analysts is to buy stock in Tiziana Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/22/2020B. RileyInitiated CoverageBuy$8.00High
i
Rating by M. Mamtani at B. Riley
9/21/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $11.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/17/2020HC WainwrightReiterated RatingBuy$25.00High
i
Rating by Ram Selvaraju at HC Wainwright
7/6/2020HC WainwrightReiterated RatingBuy$25.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
6/5/2020HC WainwrightReiterated RatingBuy$25.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/29/2020HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/10/2019LaidlawSet Price TargetBuy$20.00N/A
i
Rating by Francois Brisebois at Laidlaw
12/17/2018LaidlawInitiated CoverageBuy ➝ BuyHigh
i
12/14/2018HC WainwrightReiterated RatingBuyMedium
i
Rating by R. Selvaraju at HC Wainwright
(Data available from 3/4/2016 forward)
Tiziana Life Sciences logo
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Read More

Today's Range

Now: $2.80
$2.73
$3.11

50 Day Range

MA: $3.67
$2.88
$4.73

52 Week Range

Now: $2.80
$0.62
$12.17

Volume

205,269 shs

Average Volume

1,437,124 shs

Market Capitalization

$179.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Tiziana Life Sciences?

The following Wall Street research analysts have issued research reports on Tiziana Life Sciences in the last twelve months: B. Riley, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for TLSA.

What is the current price target for Tiziana Life Sciences?

2 Wall Street analysts have set twelve-month price targets for Tiziana Life Sciences in the last year. Their average twelve-month price target is $9.50, suggesting a possible upside of 239.3%. HC Wainwright has the highest price target set, predicting TLSA will reach $11.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $8.00 for Tiziana Life Sciences in the next year.
View the latest price targets for TLSA.

What is the current consensus analyst rating for Tiziana Life Sciences?

Tiziana Life Sciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TLSA will outperform the market and that investors should add to their positions of Tiziana Life Sciences.
View the latest ratings for TLSA.

What other companies compete with Tiziana Life Sciences?

How do I contact Tiziana Life Sciences' investor relations team?

Tiziana Life Sciences' physical mailing address is 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB. The company's listed phone number is 44-20-7495-2379 and its investor relations email address is [email protected] The official website for Tiziana Life Sciences is www.tizianalifesciences.com.